HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
INSIDE INDUSTRY
Imagion Biosystems initiates regulatory communications for first-in-human study
Imagion Biosystems Limited, an Australian biotechnology company dedicated to improving healthcare through the earlier detection of cancer, has filed for a Pre-Submission with the U.S. Food and Drug Administration (FDA), the first step in gaining approval to commence its first-in-human study.

Communications with the FDA’s Centre for Devices and Radiology Health (CDRH) follow from the recent notification that Imagion’s MagSense System and Test for staging HER2 breast cancer have been designated as a “Breakthrough Device”.

Based on FDA’s previous guidance, Imagion has filed a Pre-Submission with the agency in anticipation of filing for an investigational device exemption (IDE), a U.S. regulatory requirement for human studies with medical devices. Through the submission Imagion has requested a “sprint” discussion, a facility within the Breakthrough Device program intended to expedite communication.

“The recent Breakthrough Device designation by the FDA has been very timely, allowing us to request an expedited review of our submission” said Bob Proulx, Executive Chairman. “While the designation does not change the compliance requirements, we expect it will improve the speed with which we receive feedback from the agency and reduce the risk of disruptions to our plans for undertaking a first-in-human study.”

Following a brief review of the Pre-Submission by the FDA, Imagion will be able to schedule a meeting wherein both the reviewers within the agency and Imagion can address specific questions related to the IDE.

On July 18th, 2019, Imagion announced the Breakthrough Device designation for the MagSense System and Test for staging HER2 breast cancer. To qualify for Breakthrough Device status a product must be considered to “provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions”.

Imagion’s early feasibility, first-in-human study is a critical milestone in the development of the company’s non-radioactive imaging technology which provides a non-surgical solution to identify the progression or stage of HER2 breast cancer metastases. Operationally, the company is focused on the manufacturing of nanoparticles to be used in the study, and contracting the clinical site, in preparation for commencement of the study.

 

Click here for the complete issue.

NEWS CRUNCH  
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy